Clinical Trial Update: A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission [Phase 4]

View source ↗

Summary

A Phase 4 pilot study evaluated whether stable rheumatoid arthritis patients in clinical remission could discontinue adalimumab therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Arthritis, Rheumatoid | Phase 4 | Status: COMPLETED | Results posted: 2013-11-20